Prelude Therapeutics Stock Analysis

Prelude Stock Analysis Notes

About 70.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Prelude Therapeutics recorded a loss per share of 1.68. The entity had not issued any dividends in recent years. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware. Prelude Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 112 people. To find out more about Prelude Therapeutics contact Krishna DVM at 302 467 1280 or learn more at https://preludetx.com.

Prelude Therapeutics Investment Alerts

Prelude Therapeutics Upcoming and Recent Events

Prelude Largest EPS Surprises

View All Earnings Estimates

Prelude Stock Institutional Investors

Note, although Prelude Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Prelude Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 45.45 M.

Prelude Profitablity

Management Efficiency

Prelude Therapeutics has return on total asset (ROA) of (0.4505) % which means that it has lost $0.4505 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8144) %, meaning that it created substantial loss on money invested by shareholders. Prelude Therapeutics' management efficiency ratios could be used to measure how well Prelude Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of July 21, 2025, Return On Tangible Assets is expected to decline to -0.76. In addition to that, Return On Capital Employed is expected to decline to -0.98. At present, Prelude Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 177.2 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.2 M.

Technical Drivers

As of the 21st of July, Prelude Therapeutics holds the Risk Adjusted Performance of 0.0734, coefficient of variation of 1437.83, and Semi Deviation of 5.1. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Prelude Therapeutics, as well as the relationship between them. Please check Prelude Therapeutics variance, as well as the relationship between the maximum drawdown and semi variance to decide if Prelude Therapeutics is priced some-what accurately, providing market reflects its current price of 0.872 per share. Given that Prelude Therapeutics is a hitting penny stock territory we advise to closely look at its total risk alpha.

Prelude Therapeutics Price Movement Analysis

Prelude Therapeutics Insider Trading Activities

Prelude Therapeutics Outstanding Bonds

Prelude Therapeutics Predictive Daily Indicators

Prelude Therapeutics Forecast Models

Prelude Therapeutics' time-series forecasting models are one of many Prelude Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Prelude Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Prelude Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Prelude shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Prelude Therapeutics. By using and applying Prelude Stock analysis, traders can create a robust methodology for identifying Prelude entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Prelude analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Prelude analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Prelude Therapeutics stock analysis indicators help investors evaluate how Prelude Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Prelude Therapeutics shares will generate the highest return on investment. By understating and applying Prelude Therapeutics stock analysis, traders can identify Prelude Therapeutics position entry and exit signals to maximize returns.

When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.